Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7954]

ASCO GU: Common drug improves survival in hypertensive patients with metastatic renal cell carcinoma

ASCO GU: Common drug improves survival in hypertensive patients with metastatic renal cell carcinoma

ASCO GU: Long-term data confirms radiotherapy plus anti-androgen therapy substantially improves 10- and 15-year prostate cancer survival rates

ASCO GU: Long-term data confirms radiotherapy plus anti-androgen therapy substantially improves 10- and 15-year...

ASCO GU: Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer

ASCO GU: Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer

International deal to screen potential cancer drugs using DNA ‘barcodes’

International deal to screen potential cancer drugs using DNA ‘barcodes’

Phase II trial of bevacizumab in locally advanced cervical cancer 'promising'

Phase II trial of bevacizumab in locally advanced cervical cancer 'promising'

Genomic study identifies subgroups of HER2 breast cancer with varying sensitivities to anti-HER2 treatment

Genomic study identifies subgroups of HER2 breast cancer with varying sensitivities to anti-HER2 treatment

Breakthrough announced in treatment of patient with rare type of leukaemia

Breakthrough announced in treatment of patient with rare type of leukaemia

ASCO GI: Ras status predicts response to second-line treatment with panitumumab for metastatic colorectal cancer

ASCO GI: Ras status predicts response to second-line treatment with panitumumab for metastatic colorectal cancer

ASCO GI: Pre-operative oral capecitabine chemotherapy is equivalent to infusional 5-FU for rectal cancer

ASCO GI: Pre-operative oral capecitabine chemotherapy is equivalent to infusional 5-FU for rectal cancer

ASCO GI: Adding the targeted therapy ramucirumab to standard second-line chemotherapy improves survival, quality of life for patients with metastatic gastric cancer

ASCO GI: Adding the targeted therapy ramucirumab to standard second-line chemotherapy improves survival, quality...

More from ecancer